Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Impax Fires 110 Workers as Manufacturing Shifts to Taiwan

Impax Laboratories Inc., a maker of generic drugs, will fire about 10 percent of its workforce, as the company moves production to a manufacturing plant in Taiwan.

Most of the 110 jobs lost will be at a facility in Hayward, California, the company said in a statement today. Impax had 1,125 employees at the end of 2012, when the Hayward-based company generated $582 million in annual sales.

Use of the more cost-efficient Taiwan plant led to less need for the U.S. facility, Impax said. In addition to manufacturing jobs, two dozen salespeople and managers will be fired because of a delay in regulatory approval for the Parkinson’s disease drug Rytary. The manufacturing job cuts will lead to about $15 million in annual cost savings, and the company may hire more employees if the medicine is approved.

“This reduction in our workforce was a difficult decision, but necessary to position Impax for a brighter future,” Chief Executive Officer Larry Hsu said in the statement. “We remain committed to advancing our generic and brand business pipelines and growth strategy.”

The cuts don’t affect Impax’s financial outlook for 2013, the company said.

Impax rose less than 1 percent to $18.86 at 4 p.m. New York time. The stock has fallen 8.9 percent in the past 12 months.

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.